PTO/SB/01 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

•		Attorney Docket Number	PR60375					
DECLARATION FOR	UTILITY OR	First Named Inventor	Michelle L	. DAWSON				
DESIGN	CATION	COMPLETE IF KNOWN						
PATENT APPLIC (37 CFR 1.0		Application Number						
	Declaration Submitted after Initial Filing (surcharge) (37 CFR 1.16 (e)) required)	Filing Date						
with Initial Filing		Art Unit						
		Examiner Name						
I hereby declare that:								
Each inventor's residence, mailing address, and citizenship are as stated below next to their name.								
I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:								
INHALABLE PHARMACEUTICAL FORMULATIONS EMPLOYING LACTOSE ANHYDRATE AND METHODS OF ADMINISTERING THE SAME								
		(Title of the Invention)						
the specification of which								
is attached hereto	is attached hereto							
OR  Was filed on (10/22/2004 ) as United States Application Number or PCT International								
Application Number PCT/US2004/035129 and was amended on (MM/DD/YYYY) (if applicable).								
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.								
I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation- In-part applications, material information which became available between the filing date of the prior application and the national or								
PCT international filing date of the continuation-in-part application.  I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.								
Prior Foreign Application	Country	Foreign Filing Date	Priority Not	Certified Copy				
Number(s)		(MM/DD/YYYY)	Claimed	YES	NO			
					_ <u> </u>			
Additional foreign application	Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02/B attached hereto:							

[Page 1 of 2]

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Country

US

PTO/SB/01 (08-03) Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. **DECLARATION – Utility or Design Patent Application** Direct all correspondence to: Customer Number 23347 OR Correspondence address below Name Address State ZIP City Fax Country Telephone I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. NAME OF SOLE OR FIRST INVENTOR: A petition has been filed for this unsigned inventor Given Name **Family Name** Or Surname (first and middle [if any]) DAWSON Michelle L Inventor's Signature MMRDOS Citizenship Residence: City State Country Ware GB GB Mailing Address c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398 City State ZIP Country Research Triangle Park NC 27709 US NAME OF SECOND INVENTOR: A petition has been filed for this unsigned inventor Given Name Family Name (first and middle [if any]) Or Surname Trevor C. ROCHE Inventor's Date Signature Residence: City State Citizenship Country Ware GB GB Mailing Address c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398

27709

supplemental Additional Inventor(s) sheet(s) PTO/SB/02S or 02LR attached hereto

State

NC

Research Triangle Park

Additional inventors are being named on the

PTO/SB/02A (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. ADDITIONAL INVENTOR(S) DECLARATION Supplemental Sheet Page 3 of 3 Name of Additional Joint Inventor, if any: A petition has been filed for this unsigned inventor Family Name or Surname Given Name (first and middle [if any]) WHITAKER Mark Inventor's Signature x Residence: City State Country Citizenship GB GB Ware Mailing Address c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398 City State ZIP Country Research Triangle Park NC 27709 US Name of Additional Joint Inventor, if any: A petition has been filed for this unsigned inventor Given Name (first and middle [if any]) Family Name or Surname **CHIDAVAENZI** Owen Chisora Inventor's 16 May 2005 Signature Residence: City Citizenship State Country GB ZW Mailing Address c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398 Country Research Triangle Park NC 27709 US Name of Additional Joint Inventor, if any: A petition has been filed for this unsigned inventor Given Name (first and middle [if any]) Family Name or Surname Inventor's Signature x Date x Residence: City State Country Citizenship

State

Zip

Country

Mailing Address

City

PTO/SB/01 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Attorney Docket Number PR60375						
DECLARATION FOR		First Named Inventor	. DAWSON					
DESIGN	CATION	COMPLETE IF KNOWN						
PATENT APPLI (37 CFR 1.		Application Number						
Submitted OR with Initial Filing	Declaration Submitted after Initial Filing (surcharge) (37 CFR 1.16 (e)) required)	Filing Date						
		Art Unit						
		Examiner Name						
I hereby declare that:								
Each inventor's residence, mailing address, and citizenship are as stated below next to their name.								
I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:								
INHALABLE PHARMACEUTICAL FORMULATIONS EMPLOYING LACTOSE ANHYDRATE AND METHODS OF ADMINISTERING THE SAME								
(Title of the Invention)								
the specification of which								
is attached hereto								
OR  Was filed on (10/22/2004 ) as United States Application Number or PCT international								
Application Number PCT/US2004/035129 and was amended on (MM/DD/YYYY) (if applicable).								
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.								
I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.								
I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.								
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy A	Attached? NO			
	<u> </u>							
Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02/B attached hereto:								

[Page 1 of 2]
This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 199	5, no persons are re	equired to respond		Patent and Tradema	ark Office; U.	PTO/SB/01 (08-03) hrough 07/31/2006, OMB 0651-0032 S. DEPARTMENT OF COMMERCE contains a valid OMB control number	
DECLA	RATION - I	Utility or D	esig	n Patent A	Applicat	tion	
Direct all correspondence to:	irect all correspondence to: Customer Number 23347		OR Corresp		Correspo	ondence address below	
Name		-					
Address							
City			State	e		ZIP	
Country	Tele	phone	<u> </u>	•		Fax	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.  NAME OF SOLE OR FIRST INVENTOR:  A petition has been filed for this unsigned inventor							
Given Name			Family Name				
(first and middle [if any])	(first and middle [if any])			Or Surname			
Michelle L.			DA	WSON		-	
Inventor's Signature						Date	
Oignature							
Residence: City		State		Country		Citizenship	
Ware				GB		GB	
Mailing Address							
c/o GlaxoSmithKline, F	ive Moore	Drive PO	Box	13398			
City	110 1110010	State		ZIP		Country	
December Triangle Barb		NO.		A7700			
Research Triangle Park NAME OF SECOND INVENTO	R· Ir-	NC		27709		US	
Given Name				filed for this uns nily Name	igned inver	ntor	
(first and middle [if any])				Surname			
Trevor C.			RO	CHE			
Inventor's	$\overline{\Lambda}$					Date	
Signature	Roche.					12 May 05.	
Residence: City	<u> </u>	State		Country		Citizenship	
Ware				GB		GB	
Mailing Address							
c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398							
City		State		ZIP		Country	
Research Triangle Park		NC		27709		US	
Additional inventors are being name	don the sum		l Invent		VCB/000 0	121 R attached hereto	